Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

IF 9.3 1区医学 Q1 ONCOLOGY

European urology oncology Pub Date : 2025-09-20 DOI:10.1016/j.euo.2025.07.007

Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler, Soha Bazyar, Sofie Verbeke, Jo Van Dorpe, Valérie Fonteyne, Bram De Laere, Lara Hathout, Ronald Ennis, Salma K Jabbour, Biren Saraiya, Ryan Stephenson, Tina Mayer, Mark Mishra, Zaker Rana, Jason Molitoris, Ana Kiess, Daniel Y Song, Theodore DeWeese, Kenneth J Pienta, Phuoc T Tran, Alejandro Berlin, Cem Onal, Piet Ost, Matthew P Deek

{"title":"Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.","authors":"Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler, Soha Bazyar, Sofie Verbeke, Jo Van Dorpe, Valérie Fonteyne, Bram De Laere, Lara Hathout, Ronald Ennis, Salma K Jabbour, Biren Saraiya, Ryan Stephenson, Tina Mayer, Mark Mishra, Zaker Rana, Jason Molitoris, Ana Kiess, Daniel Y Song, Theodore DeWeese, Kenneth J Pienta, Phuoc T Tran, Alejandro Berlin, Cem Onal, Piet Ost, Matthew P Deek","doi":"10.1016/j.euo.2025.07.007","DOIUrl":null,"url":null,"abstract":"<p><p>Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.07.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.

查看原文本刊更多论文

有或没有雄激素剥夺治疗的转移导向治疗反应的基因组预测因子。

转移导向治疗（MDT）是异时性寡转移性去势敏感前列腺癌（omCSPC）的一种新兴治疗选择，可以延迟进展时间和启动雄激素剥夺治疗（ADT）的需要。然而，MDT和ADT协同的最佳方法尚不清楚，需要更好的MDT个性化。我们研究了联合ADT和MDT的作用，以及基因组改变提供MDT反应的预后和预测信息的能力。我们发现TP53、BRCA1/2、ATM和Rb1的高风险（HiRi）突变是omCSPC的不良预后标志物。此外，携带HiRi突变的患者从添加ADT到MDT中获得了更大的益处，这表明这些改变是治疗强化的预测性生物标志物。我们的研究结果表明，遗传生物标志物可能有助于omCSPC患者的治疗个性化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format